



Thursday, September 29, 2011

Australian Securities Exchange Announcement

PRESS RELEASE

KEY PUBLICATION IN 'RED JOURNAL' SUPPORTS L-DEX TESTING

International Journal of Radiation Oncology, Biology, & Physics
(The Red Journal)

A critical review article supporting the use of L-Dex technology is now available in the latest edition of the prestigious "Red Journal". Written by clinicians and researchers at the William Beaumont Hospital in the United States, it provides a review of the peer-reviewed scientific literature and finds L-Dex testing superior to current traditional techniques of measure for arm related lymphoedema in breast cancer patients. The article in the journal is titled 'Breast Cancer Related Arm Lymphedema: Incidence Rates, Diagnostic Techniques, Optimal Management and Risk Reduction Strategies', and is now available in the on-line version of the journal at: ([www.redjournal.org/article/S0360-3016\(11\)02784-2/abstract](http://www.redjournal.org/article/S0360-3016(11)02784-2/abstract)).

The publication reviews the current literature in the area of clinical assessment of unilateral lymphoedema associated with breast cancer patients and treatment modalities. The article addresses the short comings of existing conventional forms of measurement and the benefits of newer technology like bioimpedance spectroscopy (BIS) for facilitating risk reduction strategies like pre-emptive care models. It offers a concise summary for shareholders to review the latest data addressing why BIS is an optimal, contemporary recommendation for subclinical assessment and for enabling strategies to reduce the risk of breast cancer related lymphoedema (BCRL) in these patients.

Among the notable comments in the review is the following statement: "Risk reduction strategies need to incorporate treatment and patient factors that increase BCRL and include proactive surveillance and diagnosis to increase the percentage of patients who are diagnosed with subclinical disease."

The publication suggests that bioimpedance spectroscopy be adopted as a standardised method for the clinical assessment of lymphoedema, noting that the L-Dex technology is well positioned with respect to specificity, accuracy, precision, repeatability, and sensitivity.

The review goes on to say, "BIS (formally known as multifrequency bioimpedance analysis) has emerged as a potentially disease changing clinical assessment

5735201/1In Australia:
ImpediMed Limited
Unit 1, 50 Parker Court
Pinkenba, QLD 4008
Phone : +61-7-3860-3700

ASX CODE: IPD

For personal use only

modality that addresses many of the shortcomings of previous traditional assessment measures.”.....“BIS, unlike many traditional assessment tools, provides a true measure of extracellular volume and measurements are unaffected by weight changes or changes in the muscle/fat ratio.”

The case is well made in the critical review for the adoption of L-Dex for the assessment of lymphoedema post-breast cancer treatment. It should be acknowledged that bioimpedance (BIS), in common with the other assessment modalities, should not be considered as providing the definitive diagnostic criterion but as an early marker of the disease for risk reduction strategies.

ImpediMed CEO Greg Brown said, “This publication is a major clinical support for positioning L-Dex as an optimal tool for the pre-emptive care model for breast cancer patients. This is the basis of our value proposition and further supports our efforts with third party payers. The publication supports the use of BIS for aiding in the clinical assessment of lymphoedema. Awareness of pre-surgical assessment, education and ongoing surveillance is growing, and ImpediMed is well positioned to offer the first FDA cleared device to help aid in pre-emptive care with its L-Dex[®] devices.”

ENDS

L-Dex[®] is a trademark of ImpediMed Limited.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.

For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and New Zealand and may not be distributed or released in the United States. This announcement does not constitute promotion for the use of BIS devices in the United States or in any other jurisdiction in which such device clearance has not been obtained.

5735201/1In Australia:
ImpediMed Limited
Unit 1, 50 Parker Court
Pinkenba, QLD 4008
Phone : +61-7-3860-3700

ASX CODE: IPD